Molecular mechanisms and therapeutical implications of intramembrane receptor/receptor interactions among heptahelical receptors with examples from the …
The molecular basis for the known intramembrane receptor/receptor interactions among G
protein-coupled receptors was postulated to be heteromerization based on receptor subtype …
protein-coupled receptors was postulated to be heteromerization based on receptor subtype …
Adenosine A2A Antagonist: A novel antiparkinsonian agent that does not provoke dyskinesia in Parkinsonian monkeys
T Kanda, MJ Jackson, LA Smith… - Annals of …, 1998 - Wiley Online Library
Abstract Treatment of Parkinson's disease with L‐dopa therapy leads to long‐term
complications, including loss of drug efficacy and the onset of dyskinesia. Adenosine A2A …
complications, including loss of drug efficacy and the onset of dyskinesia. Adenosine A2A …
Role of high-affinity receptors and membrane transporters in nonsynaptic communication and drug action in the central nervous system
ES Vizi - Pharmacological Reviews, 2000 - ASPET
Neurochemical and morphological evidence has shown that some neurotransmitters or
substances may be released from both synaptic and nonsynaptic sites for diffusion to target …
substances may be released from both synaptic and nonsynaptic sites for diffusion to target …
Randomized trial of the adenosine A2A receptor antagonist istradefylline in advanced PD
Objective: To evaluate the safety and efficacy of the adenosine A2A receptor antagonist
istradefylline (KW-6002) in patients with levodopa-treated Parkinson's disease (PD) with …
istradefylline (KW-6002) in patients with levodopa-treated Parkinson's disease (PD) with …
Therapeutic potential of adenosine A2A receptor antagonists in Parkinson's disease
K Xu, E Bastia, M Schwarzschild - Pharmacology & therapeutics, 2005 - Elsevier
In the pursuit of improved treatments for Parkinson's disease (PD), the adenosine A2A
receptor has emerged as an attractive nondopaminergic target. Based on the compelling …
receptor has emerged as an attractive nondopaminergic target. Based on the compelling …
Ultrastructural localization of adenosine A2A receptors suggests multiple cellular sites for modulation of GABAergic neurons in rat striatum
Activation of adenosine A2A receptors (A2AR) has been shown to antagonize the function of
D2 dopaminergic regulation of striatal γ‐aminobutyric acid (GABA)‐ergic output and, thus …
D2 dopaminergic regulation of striatal γ‐aminobutyric acid (GABA)‐ergic output and, thus …
Synaptic transmission in the striatum: from plasticity to neurodegeneration
P Calabresi, D Centonze, P Gubellini, GA Marfia… - Progress in …, 2000 - Elsevier
Striatal neurones receive myriad of synaptic inputs originating from different sources.
Massive afferents from all areas of the cortex and the thalamus represent the most important …
Massive afferents from all areas of the cortex and the thalamus represent the most important …
Adenosine-dopamine interactions in the ventral striatum Implications for the treatment of schizophrenia: Implications for the treatment of schizophrenia
S Ferré - Psychopharmacology, 1997 - Springer
The ventral striatum is included in brain circuits which connect brain areas classically
ascribed to the motor or to the limbic system. In fact, the ventral striatum is involved in the …
ascribed to the motor or to the limbic system. In fact, the ventral striatum is involved in the …
The Pharmacological Potential of Adenosine A2A Receptor Antagonists for Treating Parkinson's Disease
A Mori, JF Chen, S Uchida, C Durlach, SM King… - Molecules, 2022 - mdpi.com
The adenosine A2A receptor subtype is recognized as a non-dopaminergic
pharmacological target for the treatment of neurodegenerative disorders, notably …
pharmacological target for the treatment of neurodegenerative disorders, notably …
Neuroprotection by adenosine A2A receptor blockade in experimental models of Parkinson's disease
K Ikeda, M Kurokawa, S Aoyama… - Journal of …, 2002 - Wiley Online Library
Adenosine A2A receptors are abundant in the caudate‐putamen and involved in the motor
control in several species. In MPTP‐treated monkeys, A2A receptor‐blockade with an …
control in several species. In MPTP‐treated monkeys, A2A receptor‐blockade with an …